Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Sylmar › NPI 1285845982
Hospital

County of Los Angeles

County of Los Angeles was paid $8.39M by Medicaid between Jan 2018 and Dec 2024, across 540 billing codes. Its largest line is 0450, Emergency room services — 22% of everything it billed.

33Billing provider infoCOUNTY OF LOS ANGELES
SYLMAR, CA 91342
33aNPI1285845982assigned 05/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.39M
24GClaims1,959,422
24DCodes billed540
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#198 of 410
Median peer was paid$6.90M
This provider vs. median1.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201898,581$0.00
2019161,245$293K
2020206,996$831K
2021277,539$1.12M
2022343,069$1.85M
2023416,156$2.27M
2024incomplete455,836$2.03M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
0450 Emergency room services 22% 38,443 33,913 $1.85M
74174 6.4% 8,574 7,707 $540K
99205 Prolong outpt/office vis 5.1% 4,610 4,216 $430K
G9008 Coordinated care fee, physician coordinated care oversight services 2.6% 9,115 5,992 $222K
70450 Computed tomography, head or brain; without contrast material 2.5% 6,224 5,633 $210K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 2.5% 37,681 32,013 $210K
99199 Unlisted special service, procedure or report 2.4% 3,924 3,539 $199K
0510 2.4% 11,240 10,048 $197K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 2.2% 5,608 5,028 $183K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 1.9% 16,186 15,284 $155K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 1.8% 6,800 6,272 $150K
80048 Basic metabolic panel (calcium, ionized) 1.8% 40,835 33,760 $150K
528 more codes
99284 Emergency room visit (serious) 1.6% 19,695 $132K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.5% 37,533 $126K
J9271 Injection, pembrolizumab, 1 mg 1.4% 768 $114K
99283 Emergency room visit (moderate) 1.3% 20,634 $108K
76705 Ultrasound, abdominal, real time with image documentation; limited 1.3% 5,349 $107K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 1.2% 1,993 $99K
Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg 1.0% 824 $86K
0760 <1% 3,183 $80K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 2,642 $75K
71046 Radiologic examination, chest; 2 views <1% 15,717 $67K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 5,854 $67K
71045 Radiologic examination, chest; single view <1% 19,612 $66K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 5,754 $66K
59025 Fetal non-stress test <1% 7,846 $64K
71275 Computed tomographic angiography, chest, with contrast material <1% 1,548 $60K
99221 <1% 2,025 $56K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 5,251 $56K
80076 <1% 11,647 $56K
93971 <1% 2,810 $55K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 2,408 $54K
84484 <1% 6,607 $53K
72125 Computed tomography, cervical spine; without contrast material <1% 961 $52K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 1,811 $52K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 1,442 $49K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 460 $47K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 6,517 $42K
83880 <1% 2,107 $40K
J1815 Injection, insulin, per 5 units <1% 1,083 $38K
0111 <1% 234 $37K
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg <1% 2,008 $36K
83690 <1% 6,644 $34K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 882 $34K
86780 <1% 4,034 $33K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 2,205 $29K
87086 Culture, bacterial; quantitative colony count, urine <1% 8,212 $29K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 3,602 $28K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 14,754 $27K
J7030 Infusion, normal saline solution , 1000 cc <1% 20,534 $27K
90792 Psychiatric diagnostic evaluation with medical services <1% 562 $27K
70551 Magnetic resonance imaging, brain; without contrast material <1% 349 $27K
76827 <1% 2,027 $26K
76830 Ultrasound, transvaginal <1% 1,060 $25K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 11,918 $25K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 10,238 $24K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 10,526 $23K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 4,111 $23K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 749 $22K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 4,263 $22K
86480 <1% 3,631 $22K
73564 <1% 3,426 $22K
73610 <1% 3,771 $21K
81001 <1% 15,685 $21K
76801 <1% 1,125 $21K
73630 <1% 5,794 $20K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 763 $20K
80053 Comprehensive metabolic panel <1% 16,473 $20K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 24,583 $19K
J2270 Injection, morphine sulfate, up to 10 mg <1% 6,536 $19K
81025 <1% 6,757 $19K
71250 <1% 573 $19K
87522 Neg quan hep c or qual rna <1% 3,439 $19K
S5551 Insulin, most rapid onset (lispro or aspart); 5 units <1% 5,021 $18K
73130 <1% 4,233 $18K
73110 <1% 3,589 $18K
J9306 Injection, pertuzumab, 1 mg <1% 93 $18K
0250 <1% 24,388 $17K
0516 <1% 598 $17K
93970 <1% 843 $17K
88342 <1% 2,380 $17K
73030 <1% 3,250 $17K
83605 <1% 2,083 $16K
J2560 Injection, phenobarbital sodium, up to 120 mg <1% 297 $15K
Q5116 Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg <1% 390 $15K
86141 <1% 3,930 $14K
72100 <1% 2,060 $14K
83036 Hemoglobin; glycosylated (A1C) <1% 16,070 $13K
84702 <1% 2,088 $13K
85610 <1% 18,920 $13K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 6,932 $13K
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg <1% 331 $13K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 10,938 $13K
86703 <1% 4,095 $12K
76770 <1% 886 $12K
90715 <1% 1,012 $12K
94760 <1% 4,696 $11K
87507 <1% 108 $11K
83735 <1% 8,764 $11K
76642 <1% 812 $11K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 4,379 $10K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 1,911 $10K
90677 <1% 2,405 $10K
76870 <1% 636 $10K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 1,238 $10K
J7120 Ringers lactate infusion, up to 1000 cc <1% 16,064 $10K
86850 <1% 3,347 $10K
73590 <1% 1,387 $9K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 581 $9K
80305 <1% 3,045 $9K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 157 $9K
P9016 Red blood cells, leukocytes reduced, each unit <1% 277 $9K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 33 $9K
70498 <1% 167 $9K
80061 Lipid panel <1% 10,760 $9K
85027 <1% 8,935 $9K
73080 <1% 1,237 $9K
70491 <1% 196 $9K
84443 Thyroid stimulating hormone (TSH) <1% 2,729 $9K
86901 <1% 3,907 $9K
90651 <1% 1,168 $9K
80422 <1% 877 $8K
87186 <1% 2,053 $8K
G9012 Other specified case management service not elsewhere classified <1% 66 $8K
67028 Intravitreal injection of a pharmacologic agent <1% 166 $8K
73562 <1% 1,252 $8K
86900 <1% 3,694 $7K
87040 <1% 762 $7K
99232 Hospital visit by a doctor, follow-up day <1% 197 $7K
76512 <1% 475 $7K
92134 <1% 4,753 $6K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 4,065 $6K
J2704 Injection, propofol, 10 mg <1% 4,972 $6K
70486 <1% 111 $6K
73700 <1% 138 $6K
J1170 Injection, hydromorphone, up to 4 mg <1% 5,509 $6K
85730 <1% 2,499 $6K
J1050 Injection, medroxyprogesterone acetate, 1 mg <1% 1,661 $6K
73502 <1% 616 $6K
99213 Doctor's office visit, returning patient (routine) <1% 106,403 $6K
77066 Tomosynthesis, mammo <1% 229 $6K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,953 $5K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 22,545 $5K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 12,324 $5K
J9217 Leuprolide acetate (for depot suspension), 7.5 mg <1% 872 $5K
36415 Collection of venous blood by venipuncture <1% 210,764 $5K
76857 <1% 470 $5K
70496 <1% 55 $5K
J2795 Injection, ropivacaine hydrochloride, 1 mg <1% 110 $5K
J0780 Injection, prochlorperazine, up to 10 mg <1% 1,940 $5K
87340 <1% 2,097 $5K
86592 <1% 2,347 $5K
73090 <1% 581 $5K
86593 <1% 1,414 $5K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 109 $5K
73140 <1% 1,170 $5K
99381 <1% 493 $4K
87070 <1% 1,842 $4K
99231 Subsequent hospital care, per day, straightforward or low complexity <1% 444 $4K
J2505 Injection, pegfilgrastim, 6 mg <1% 21 $4K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 83 $4K
90723 <1% 1,131 $4K
84100 <1% 3,685 $4K
81003 <1% 4,108 $4K
87088 <1% 3,446 $4K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 6,563 $4K
88142 <1% 4,390 $4K
Q3014 Telehealth originating site facility fee <1% 621 $4K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 6,973 $4K
51798 <1% 692 $4K
83970 <1% 1,032 $4K
92250 <1% 2,672 $4K
86765 <1% 672 $4K
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) <1% 1,023 $4K
76536 <1% 491 $4K
82728 <1% 2,632 $3K
84439 <1% 1,714 $3K
90750 <1% 1,649 $3K
77065 Tomosynthesis, mammo <1% 282 $3K
86762 <1% 472 $3K
92557 <1% 2,927 $3K
J3475 Injection, magnesium sulfate, per 500 mg <1% 4,182 $3K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 2,680 $3K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 173 $3K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 54 $3K
J7050 Infusion, normal saline solution, 250 cc <1% 17,306 $3K
74018 <1% 1,024 $3K
81000 <1% 8,990 $3K
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 1,262 $3K
J2060 Injection, lorazepam, 2 mg <1% 3,051 $3K
73620 <1% 465 $3K
99243 <1% 1,867 $3K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 7,395 $3K
97164 <1% 4,407 $3K
P9040 Red blood cells, leukocytes reduced, irradiated, each unit <1% 180 $3K
82550 <1% 887 $2K
95806 <1% 1,468 $2K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 72 $2K
82962 <1% 7,200 $2K
73120 <1% 393 $2K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 1,178 $2K
90935 Hemodialysis procedure with single evaluation by a physician <1% 278 $2K
82607 <1% 2,039 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 19,085 $2K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 126 $2K
J1644 Injection, heparin sodium, per 1000 units <1% 6,598 $2K
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 326 $2K
82746 <1% 1,385 $2K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 518 $2K
76881 <1% 223 $2K
86787 <1% 364 $2K
83550 <1% 2,432 $2K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 503 $2K
92133 <1% 1,887 $2K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 34 $2K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 617 $2K
72040 <1% 486 $2K
81243 <1% 119 $2K
87536 <1% 172 $2K
58100 <1% 678 $2K
83540 <1% 2,478 $2K
93303 Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study <1% 323 $2K
90670 <1% 436 $2K
86706 <1% 1,539 $2K
G9920 Screening performed and negative <1% 3,261 $2K
85652 <1% 2,896 $2K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 1,749 $2K
J7297 Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg <1% 43 $2K
J1750 Injection, iron dextran, 50 mg <1% 65 $2K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 1,482 $2K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 1,732 $2K
97161 <1% 9,603 $2K
J1950 Injection, leuprolide acetate (for depot suspension), per 3.75 mg <1% 16 $2K
J3370 Injection, vancomycin hcl, 500 mg <1% 1,259 $2K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 3,273 $2K
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient <1% 1,335 $1K
87581 <1% 111 $1K
99442 <1% 47,202 $1K
87210 <1% 1,626 $1K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,943 $1K
80074 <1% 151 $1K
99244 Office or other outpatient consultation, moderate to high complexity <1% 1,262 $1K
86705 <1% 930 $1K
82570 <1% 2,645 $1K
92004 Ophthalmological services: medical examination and evaluation, comprehensive, new patient <1% 1,040 $1K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 2,148 $1K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 9,324 $1K
99024 <1% 483 $1K
85378 <1% 259 $1K
99203 Doctor's office visit, new patient (routine) <1% 13,320 $1K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 4,839 $1K
83021 <1% 150 $1K
82043 <1% 4,228 $1K
97010 <1% 15,094 $1K
J1630 Injection, haloperidol, up to 5 mg <1% 1,690 $1K
93247 <1% 1,244 $1K
86923 <1% 1,399 $1K
86160 <1% 401 $1K
82274 <1% 7,850 $1K
94729 <1% 783 $1K
99385 <1% 748 $1K
86039 <1% 404 $1K
27502 <1% 13 $1K
95811 <1% 372 $1K
76775 <1% 74 $1K
87205 <1% 708 $1K
94010 <1% 1,689 $1K
90686 <1% 4,279 $997.50
99204 Doctor's office visit, new patient (more involved) <1% 8,925 $987.49
87081 <1% 677 $971.35
99441 <1% 22,097 $960.60
J0690 Injection, cefazolin sodium, 500 mg <1% 4,439 $959.50
73060 <1% 171 $949.94
99238 Hospital discharge day management, 30 minutes or less <1% 26 $948.96
85007 <1% 892 $944.96
88307 <1% 337 $944.40
99443 <1% 37,471 $942.08
J1940 Injection, furosemide, up to 20 mg <1% 1,934 $933.84
93017 <1% 560 $914.94
82540 <1% 4,232 $913.00
92082 <1% 281 $908.07
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 3,470 $904.12
90707 <1% 527 $891.54
88187 <1% 393 $867.49
90648 <1% 1,456 $833.09
90472 Immunization administration, each additional vaccine (list separately) <1% 1,575 $821.94
82565 <1% 5,083 $810.63
88312 <1% 395 $807.51
90716 <1% 528 $804.35
J2785 Injection, regadenoson, 0.1 mg <1% 157 $776.00
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 984 $750.20
76942 <1% 355 $744.78
86753 <1% 139 $743.69
82105 <1% 236 $739.37
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 19 $727.60
84703 <1% 393 $725.34
83615 <1% 765 $719.53
90674 <1% 369 $716.75
99383 <1% 237 $700.44
96375 Therapeutic injection; each additional sequential IV push <1% 159 $661.55
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 1,397 $652.82
J3489 Injection, zoledronic acid, 1 mg <1% 1,417 $640.03
87150 <1% 195 $638.45
76499 <1% 51 $634.98
S0164 Injection, pantoprazole sodium, 40 mg <1% 767 $618.62
92227 <1% 2,447 $612.78
J9070 Cyclophosphamide, 100 mg <1% 87 $609.47
78014 <1% 171 $605.62
85008 <1% 665 $603.23
51702 <1% 42 $573.86
99214 Doctor's office visit, returning patient (more involved) <1% 45,371 $573.57
88173 <1% 400 $548.25
87338 <1% 1,698 $539.97
97162 <1% 2,219 $532.08
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 355 $517.76
84153 <1% 457 $513.79
J8540 Dexamethasone, oral, 0.25 mg <1% 1,990 $486.61
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 186 $473.68
J3490 Unclassified drugs <1% 512 $464.98
73000 <1% 132 $439.54
J3480 Injection, potassium chloride, per 2 meq <1% 1,213 $437.13
J7060 5% dextrose/water (500 ml = 1 unit) <1% 1,531 $413.56
84550 <1% 601 $408.79
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 181 $402.89
88304 <1% 1,289 $399.17
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 2,136 $396.20
74170 <1% 13 $377.33
99245 <1% 261 $376.98
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 32,749 $376.51
88141 <1% 486 $371.38
84403 <1% 153 $367.40
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen <1% 11,600 $366.61
73503 <1% 30 $363.76
73600 <1% 52 $349.48
S5550 Insulin, rapid onset, 5 units <1% 671 $319.89
87102 <1% 98 $296.25
J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg <1% 438 $292.40
92235 <1% 51 $287.51
73660 <1% 60 $284.73
73560 <1% 52 $282.34
J1650 Injection, enoxaparin sodium, 10 mg <1% 4,415 $282.32
0401 <1% 30 $278.44
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 218 $275.04
96417 <1% 29 $270.14
94726 <1% 216 $267.58
84146 <1% 71 $266.68
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 59 $264.94
85014 <1% 973 $262.19
85018 <1% 979 $261.93
82784 <1% 388 $260.01
87481 <1% 17 $257.94
90734 <1% 655 $255.33
90746 <1% 140 $251.46
0124A <1% 251 $238.80
92025 <1% 147 $226.41
J2370 Injection, phenylephrine hcl, up to 1 ml <1% 985 $222.16
97166 <1% 917 $220.64
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 1,950 $208.45
82378 <1% 32 $206.78
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg <1% 1,350 $206.60
82040 <1% 332 $205.81
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 1,760 $205.64
75989 <1% 12 $203.83
90633 <1% 952 $203.76
J9267 Injection, paclitaxel, 1 mg <1% 1,185 $198.12
J9263 Injection, oxaliplatin, 0.5 mg <1% 538 $197.88
93926 <1% 211 $192.88
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 96,286 $187.09
85044 <1% 227 $170.64
97116 <1% 514 $170.49
96415 <1% 28 $170.21
81002 <1% 327 $170.19
76519 <1% 42 $165.81
J0330 Injection, succinylcholine chloride, up to 20 mg <1% 780 $163.94
0300 <1% 3,781 $161.96
90739 <1% 557 $160.00
92550 <1% 152 $157.95
86431 <1% 145 $154.31
87184 <1% 49 $152.35
J9045 Injection, carboplatin, 50 mg <1% 1,019 $151.69
A9575 Injection, gadoterate meglumine, 0.1 ml <1% 151 $143.39
97168 <1% 914 $139.75
84481 <1% 42 $138.35
99382 <1% 113 $134.52
86635 <1% 69 $132.56
99201 <1% 731 $125.07
86235 <1% 41 $124.03
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 16 $114.76
J9060 Injection, cisplatin, powder or solution, 10 mg <1% 30 $110.50
72170 <1% 13 $110.11
86225 <1% 83 $107.95
J9035 Injection, bevacizumab, 10 mg <1% 251 $106.00
94618 <1% 317 $100.80
88112 <1% 156 $98.69
82248 <1% 89 $93.60
85041 <1% 103 $92.52
74183 <1% 27 $86.82
92504 <1% 609 $86.56
83521 <1% 73 $83.73
84155 <1% 519 $80.88
90700 <1% 429 $80.72
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram <1% 1,416 $80.42
77080 <1% 220 $78.78
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 140 $74.90
76376 <1% 852 $74.67
92083 <1% 185 $74.24
84450 <1% 138 $71.68
J9190 Injection, fluorouracil, 500 mg <1% 198 $70.68
88313 <1% 17 $70.18
76825 <1% 25 $69.42
99234 <1% 19 $68.20
P9047 Infusion, albumin (human), 25%, 50 ml <1% 84 $68.00
76000 <1% 218 $63.32
92015 Determination of refractive state <1% 157 $62.47
J1453 Injection, fosaprepitant, 1 mg <1% 1,543 $62.39
94660 <1% 36 $58.52
99242 <1% 28 $58.03
J0456 Injection, azithromycin, 500 mg <1% 70 $57.56
97018 <1% 1,308 $57.49
J7042 5% dextrose/normal saline (500 ml = 1 unit) <1% 18 $53.70
0636 <1% 5,993 $49.16
J0640 Injection, leucovorin calcium, per 50 mg <1% 161 $48.51
84460 <1% 127 $48.06
83921 <1% 50 $43.79
98968 <1% 2,021 $42.49
51736 <1% 24 $42.19
97165 <1% 303 $41.16
83001 <1% 12 $39.70
97760 <1% 294 $38.02
99241 <1% 36 $34.76
J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) <1% 60 $34.44
90656 <1% 1,737 $33.14
A9152 Single vitamin/mineral/trace element, oral, per dose, not otherwise specified <1% 399 $26.76
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 80 $25.81
83721 <1% 56 $20.80
Q0144 Azithromycin dihydrate, oral, capsules/powder, 1 gram <1% 32 $20.17
92567 <1% 270 $19.80
98966 <1% 1,025 $19.72
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg <1% 26 $19.00
S5553 Insulin, long acting; 5 units <1% 296 $16.77
85060 <1% 26 $12.63
J7642 Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram <1% 1,435 $9.69
90696 <1% 365 $8.91
90710 <1% 379 $8.91
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 391 $8.78
88300 <1% 184 $7.32
82247 <1% 23 $4.97
J0612 Injection, calcium gluconate, not otherwise specified, 10 mg <1% 15 $4.51
S0028 Injection, famotidine, 20 mg <1% 457 $2.83
S0030 Injection, metronidazole, 500 mg <1% 365 $1.98
0771 0% 5,657 $0.00
20610 0% 149 $0.00
3079F 0% 2,009 $0.00
99384 0% 126 $0.00
0100 0% 9,485 $0.00
91307 0% 460 $0.00
1220F 0% 465 $0.00
3052F 0% 811 $0.00
96161 0% 1,731 $0.00
3074F 0% 17,781 $0.00
31231 0% 105 $0.00
3075F 0% 4,214 $0.00
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder 0% 42 $0.00
80320 0% 52 $0.00
98967 0% 2,622 $0.00
0110 0% 903 $0.00
90694 0% 62 $0.00
T1014 Telehealth transmission, per minute, professional services bill separately 0% 446 $0.00
81015 0% 428 $0.00
99386 0% 398 $0.00
J2357 Injection, omalizumab, 5 mg 0% 409 $0.00
0074A 0% 28 $0.00
59414 0% 198 $0.00
J9312 Injection, rituximab, 10 mg 0% 45 $0.00
91317 0% 37 $0.00
0206 0% 47 $0.00
91305 0% 83 $0.00
93294 0% 13 $0.00
3080F 0% 654 $0.00
99412 0% 104 $0.00
92551 0% 26 $0.00
1111F 0% 12,388 $0.00
59410 0% 42 $0.00
3044F 0% 6,245 $0.00
86335 0% 13 $0.00
36410 0% 75 $0.00
2001F 0% 13 $0.00
52000 0% 14 $0.00
J0610 Injection, calcium gluconate (fresenius kabi), per 10 ml 0% 19 $0.00
99464 0% 15 $0.00
91315 0% 100 $0.00
80502 0% 20 $0.00
99465 0% 15 $0.00
92587 0% 17 $0.00
J9299 Injection, nivolumab, 1 mg 0% 37 $0.00
80329 0% 24 $0.00
90698 0% 12 $0.00
J0461 Injection, atropine sulfate, 0.01 mg 0% 26 $0.00
77062 0% 1,461 $0.00
31575 0% 413 $0.00
J2590 Injection, oxytocin, up to 10 units 0% 133 $0.00
95810 Polysomnography; sleep staging with 4 or more additional parameters 0% 113 $0.00
36600 0% 674 $0.00
J9000 Injection, doxorubicin hydrochloride, 10 mg 0% 17 $0.00
91300 0% 2,064 $0.00
98960 0% 4,374 $0.00
99397 0% 27 $0.00
97602 0% 608 $0.00
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years 0% 1,442 $0.00
96160 0% 532 $0.00
3051F 0% 1,398 $0.00
0424 0% 100 $0.00
3078F 0% 14,111 $0.00
J9355 Injection, trastuzumab, excludes biosimilar, 10 mg 0% 260 $0.00
0120 0% 2,102 $0.00
93041 0% 520 $0.00
91312 0% 600 $0.00
83655 0% 87 $0.00
J9171 Injection, docetaxel, 1 mg 0% 15 $0.00
3077F 0% 3,383 $0.00
90653 0% 325 $0.00
J0694 Injection, cefoxitin sodium, 1 gm 0% 12 $0.00
3046F 0% 1,332 $0.00
93882 0% 24 $0.00
0731 0% 123 $0.00
86334 0% 39 $0.00
86922 0% 17 $0.00
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 0% 114 $0.00
90473 0% 40 $0.00
J9206 Injection, irinotecan, 20 mg 0% 25 $0.00
93880 0% 28 $0.00
92555 0% 31 $0.00
0200 0% 46 $0.00
93978 0% 12 $0.00
84145 0% 19 $0.00
91308 0% 23 $0.00
90661 0% 243 $0.00
99173 0% 12 $0.00
C9257 Injection, bevacizumab, 0.25 mg 0% 30 $0.00
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg 0% 48 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMCKENZIE, KIMBERLY (CEO)
Parent organizationCOUNTY OF LOS ANGELES